Cargando…

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation

PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomaa, Sameh, Lopez, AnaMaria, Slamon, Rachel, Smith, Rita, Telushi, Elma, Lapitan, Emmanuel, Nightingale, Ginah, Miller, Suzanne, Wen, Kuang-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915802/
https://www.ncbi.nlm.nih.gov/pubmed/36778385
http://dx.doi.org/10.21203/rs.3.rs-2497342/v1
_version_ 1784885975032266752
author Gomaa, Sameh
Lopez, AnaMaria
Slamon, Rachel
Smith, Rita
Telushi, Elma
Lapitan, Emmanuel
Nightingale, Ginah
Miller, Suzanne
Wen, Kuang-Yi
author_facet Gomaa, Sameh
Lopez, AnaMaria
Slamon, Rachel
Smith, Rita
Telushi, Elma
Lapitan, Emmanuel
Nightingale, Ginah
Miller, Suzanne
Wen, Kuang-Yi
author_sort Gomaa, Sameh
collection PubMed
description PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positive breast cancer. However, early discontinuation of medicine is reported to range from 20% to 50%. Poor adherence has been attributed to multiple factors including presence of adverse events. We aim to report the lived experience of breast cancer survivors specifically as regards to side effects, the most reported reason for lack of adherence. METHODS: 35 breast cancer survivors on AET were interviewed. Qualitative iterative analysis was conducted using the grounded theory approach with the goal of identifying themes that emerge from the interviews and refining the question probes as needed. A codebook was developed and supplemented with interpretive codes generated through ongoing analysis of transcripts. All transcripts were coded using NVIVO qualitative data analysis software for data interpretations. RESULTS: Reported side effects associated with AET medications include hot flashes, sexual side-effects, joint pain, stiffness, cognitive function, mood changes, bone mass density decrease and fertility concerns. Women who were on AET more than 6 months reported more side effect concerns. A variety of coping strategies using over the counter medications or alternative medicines and approaches were also discussed. CONCLUSION: Tailored and timely information on potential AET-induced side effects and strategies to manage them is needed. In particular, some side effects are more prevalent by medication (e.g., joint pain in those who were taking an aromatases inhibitor). Provision of information to prepare women for the potential side effects of type of AET they are prescribed for would be helpful. IMPLICATIONS FOR CANCER SURVIVORS: As AET has been suggested for 10 years to improve surveillance and reduce recurrence, our results have implications for cancer survivors, especially the onsets of side effects and potential ways to manage them as they arise.
format Online
Article
Text
id pubmed-9915802
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-99158022023-02-11 The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation Gomaa, Sameh Lopez, AnaMaria Slamon, Rachel Smith, Rita Telushi, Elma Lapitan, Emmanuel Nightingale, Ginah Miller, Suzanne Wen, Kuang-Yi Res Sq Article PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positive breast cancer. However, early discontinuation of medicine is reported to range from 20% to 50%. Poor adherence has been attributed to multiple factors including presence of adverse events. We aim to report the lived experience of breast cancer survivors specifically as regards to side effects, the most reported reason for lack of adherence. METHODS: 35 breast cancer survivors on AET were interviewed. Qualitative iterative analysis was conducted using the grounded theory approach with the goal of identifying themes that emerge from the interviews and refining the question probes as needed. A codebook was developed and supplemented with interpretive codes generated through ongoing analysis of transcripts. All transcripts were coded using NVIVO qualitative data analysis software for data interpretations. RESULTS: Reported side effects associated with AET medications include hot flashes, sexual side-effects, joint pain, stiffness, cognitive function, mood changes, bone mass density decrease and fertility concerns. Women who were on AET more than 6 months reported more side effect concerns. A variety of coping strategies using over the counter medications or alternative medicines and approaches were also discussed. CONCLUSION: Tailored and timely information on potential AET-induced side effects and strategies to manage them is needed. In particular, some side effects are more prevalent by medication (e.g., joint pain in those who were taking an aromatases inhibitor). Provision of information to prepare women for the potential side effects of type of AET they are prescribed for would be helpful. IMPLICATIONS FOR CANCER SURVIVORS: As AET has been suggested for 10 years to improve surveillance and reduce recurrence, our results have implications for cancer survivors, especially the onsets of side effects and potential ways to manage them as they arise. American Journal Experts 2023-01-30 /pmc/articles/PMC9915802/ /pubmed/36778385 http://dx.doi.org/10.21203/rs.3.rs-2497342/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Gomaa, Sameh
Lopez, AnaMaria
Slamon, Rachel
Smith, Rita
Telushi, Elma
Lapitan, Emmanuel
Nightingale, Ginah
Miller, Suzanne
Wen, Kuang-Yi
The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title_full The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title_fullStr The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title_full_unstemmed The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title_short The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
title_sort lived experience of breast cancer patients on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915802/
https://www.ncbi.nlm.nih.gov/pubmed/36778385
http://dx.doi.org/10.21203/rs.3.rs-2497342/v1
work_keys_str_mv AT gomaasameh thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT lopezanamaria thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT slamonrachel thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT smithrita thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT telushielma thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT lapitanemmanuel thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT nightingaleginah thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT millersuzanne thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT wenkuangyi thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT gomaasameh livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT lopezanamaria livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT slamonrachel livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT smithrita livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT telushielma livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT lapitanemmanuel livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT nightingaleginah livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT millersuzanne livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation
AT wenkuangyi livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation